Search results
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
The Motley Fool via AOL· 1 day agoLuckily, sales of Rinvoq, an arthritis tablet, and Skyrizi, a psoriasis injection, offset the loss. Skyrizi sales soared 47.6% to $2.0 billion and Rinvoq sales jumped 59.3% ...
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results - Arcutis Biotherapeutics...
Benzinga· 7 days ago“Our strong performance in the first quarter, with the incredibly well-received launch of ZORYVE...
What Can I Do To Prevent Spondylolisthesis From Getting Worse? A Review By Doctors
MSN News· 7 days agoExpert opinion from Gustavo Campos Doctor of Medicine · 9 years of experience · Brazil It's...
Needham & Company LLC Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 4 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) had its target price lifted by equities researchers at Needham & Company LLC from $16.00 to $18.00 in a note issued to investors on Wednesday ...
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 3 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Mizuho from $17.00 to $18.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating ...
Coexistence of psoriatic arthritis, atopic dermatitis may offer treatment insights
Medical Xpress· 7 days agoPsoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
Urine Tests Could Be 'Enormous Step' in Diagnosing Cancer
Medscape· 10 hours agoThe next frontier in cancer detection could be the humble urine test. Emerging science suggests that...
How skin conditions like vitiligo affect mental health
WFLA· 5 days agoTAMPA (BLOOM) – May is Mental Health Month, a time to raise awareness about the critical connection...
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...
In RA Treatment, Don't Overlook Underlying CV Risks
Medscape· 5 days agoRheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic...